About Bactolife

Bactolife develops Binding Proteins that enhance gut microbiome health by targeting harmful microbes and their metabolites, addressing the global issue of antimicrobial resistance. Their solutions aim to improve health outcomes for both humans and animals by promoting a balanced gut environment.

```xml <problem> The overuse of antimicrobials is leading to a rise in antimicrobial resistance, threatening the effectiveness of treatments for infectious diseases in both humans and animals. Maintaining a healthy gut microbiome is crucial for overall health, but it is often disrupted by harmful microbes and their metabolites. </problem> <solution> Bactolife develops Binding Proteins designed to selectively target and neutralize harmful microbes and their metabolites within the gut, promoting a balanced and healthy gut microbiome. These Binding Proteins offer a targeted approach to modulate the gut environment, supporting overall health and well-being. By addressing the root cause of gut imbalance, Bactolife aims to reduce the reliance on broad-spectrum antimicrobials and mitigate the development of antimicrobial resistance. Their technology offers a proactive strategy for improving gut health and preventing dysbiosis. Bactolife's Binding Proteins can be integrated into various applications for both human and animal health. </solution> <features> - Selectively binds to harmful microbes and their metabolites in the gut - Promotes a balanced and healthy gut microbiome - Reduces the need for broad-spectrum antimicrobials - Helps to mitigate the development of antimicrobial resistance - Can be integrated into various applications for human and animal health </features> <target_audience> Bactolife's primary customers include individuals seeking to improve their gut health and reduce their reliance on antimicrobials, as well as animal health companies looking for innovative solutions to promote gut health in livestock and pets. </target_audience> ```

What does Bactolife do?

Where is Bactolife located?

Bactolife is based in Kongens Lyngby, Denmark.

When was Bactolife founded?

Bactolife was founded in 2017.

How much funding has Bactolife raised?

Bactolife has raised 44120000.

Location

Kongens Lyngby, Denmark

Founded

2017

Funding

44120000

Employees

59 employees

Major Investors

ATHOS

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Bactolife

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

bactolife.com 7K+

Crunchbase

Founded 2017 – Kongens Lyngby, Denmark

Funding

Estimated Funding

$20M+

Major Investors

ATHOS

Team (50+)

No team information available.

Company Description

Problem

The overuse of antimicrobials is leading to a rise in antimicrobial resistance, threatening the effectiveness of treatments for infectious diseases in both humans and animals. Maintaining a healthy gut microbiome is crucial for overall health, but it is often disrupted by harmful microbes and their metabolites.

Solution

Bactolife develops Binding Proteins designed to selectively target and neutralize harmful microbes and their metabolites within the gut, promoting a balanced and healthy gut microbiome. These Binding Proteins offer a targeted approach to modulate the gut environment, supporting overall health and well-being. By addressing the root cause of gut imbalance, Bactolife aims to reduce the reliance on broad-spectrum antimicrobials and mitigate the development of antimicrobial resistance. Their technology offers a proactive strategy for improving gut health and preventing dysbiosis. Bactolife's Binding Proteins can be integrated into various applications for both human and animal health.

Features

Selectively binds to harmful microbes and their metabolites in the gut

Promotes a balanced and healthy gut microbiome

Reduces the need for broad-spectrum antimicrobials

Helps to mitigate the development of antimicrobial resistance

Can be integrated into various applications for human and animal health

Target Audience

Bactolife's primary customers include individuals seeking to improve their gut health and reduce their reliance on antimicrobials, as well as animal health companies looking for innovative solutions to promote gut health in livestock and pets.